Indogenix Biosciences LLP and Jawaharlal Nehru Cancer Hospital and Research Center signed and Memorandum of Understanding (MOU) in 2019. The MOU aims to establish a collaborative clinical exploratory research project and conduct trials on cannabinoids and cancer. This makes Indogenix the first company to get ethical approval and get published in vitro international journals.
The MOU outlines the common goal of both parties to encourage the discovery, dissemination, and application of new knowledge in the field of pharmacological analysis of cannabis extract. The project is funded by Indogenix Biosciences LLP, and the research is conducted at Jawaharlal Nehru Cancer Hospital and Research Center.
Members of the Research Team
Dr N. Ganesh, Principal investigator, Department of Research, Jawaharlal Nehru Cancer Hospital & Research Centre, ldgah Hills, Bhopal, M.P
Dr S. Ravi, Chief Scientific Officer, Indogenix Bioscience LLP, Bagrods, Bhopal, M.P
Mr. Sarfaraz Hanfi, Research Project Coordinator, Indogenix Bioscience LLP, Bagroda, Bhopal, M.P
About Indogenix Biosciences LLP
Indogenix is engaged in the business of manufacturing, marketing, and selling “VIJAYA EXTRACT” under the trademark and brand name Cannabryl.
About Jawahar Lal Nehru Cancer Hospital and Research Centre
Jawaharlal Nehru Cancer Hospital and Research Centre is a healthcare institution located in Bhopal, Madhya Pradesh, India. It is dedicated to the prevention, diagnosis, and treatment of cancer. The hospital provides comprehensive cancer care services, including medical oncology, surgical oncology, radiation oncology, and palliative care.
The research center associated with the hospital focuses on advancing cancer research, exploring new treatment modalities, and conducting cannabis clinical trials. It aims to contribute to the scientific understanding of cancer and develop innovative approaches for its management.
Our Clinical Project with the Urological Center for Advanced Urological Diseases at Lake City Hospital involves the use of Cannabidiol for pain and discomfort post RIRS (Retrograde Intrarenal surgery), in the post-ureteroscopy setting, and in urological cancer for symptomatic pain management.
The aim of the cannabidiol (CBD) research studies is to evaluate the efficacy of cannabidiol's analgesic and antinociceptive properties in mitigating pain and stent discomfort in the post-RIRS and post-ureteroscopy setting. Cannabidiol's efficacy represents an alternative analgesic to opioid dependence and we intend to evaluate its anti-inflammatory and antinociceptive effects
In addition, we are working together with Soma Living Roots (Clinical Neurosciences & Transpersonal Community) on a project focused on alleviating pain, depression, and anxiety associated with end-stage cancer. The study's main objective is to investigate the impact of MCAP (Medical cannabis-assisted Psychotherapy) on treating depressive and anxiety disorders in terminally ill cancer patients.
The proposed cannabis research studies aim to extend the use of medical cannabis to a specific group of cancer patients with a guarded prognosis.
Regarding the use of medical cannabis in oncology, the effectiveness of orally administered cannabis medicine in the sublingual form or as suppositories has consistently shown positive results in relieving symptoms such as nausea, vomiting, and cancer pain that is unresponsive to opioids. While the anxiety and depression-relieving properties of medical cannabis over an extended period of time are well-documented, its unique potential for alleviating anxiety and spiritual distress related to end-of-life issues and expectations remains to be explored.
Independent case reports from cancer patients at Lake City Hospital indicate several positive outcomes, including improved appetite, reduced nausea, pain, lethargy, and fatigue. Patients also experience a sense of well-being, euphoria, alertness, heightened awareness, and insight into their own condition.
Furthermore, patients report feeling more secure and better equipped to manage aversive memory triggers and anxiety associated with their disease. They also describe a sense of spiritual calmness following the therapeutic administration of medical cannabis during the process of psycho-synthesis.